{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:12:34Z","timestamp":1794485554125,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clinthera.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T01:30:43Z","timestamp":1521855043000},"page":"593-602.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Burden of Illness Associated with Tenosynovial Giant Cell Tumors"],"prefix":"10.1016","volume":"40","author":[{"given":"Tanya M.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.03.001_bib1","first-page":"547","article-title":"Synovial colony-stimulating factor-1 mRNA expression in diffuse pigmented villonodular synovitis","volume":"29","author":"Molena","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib2","first-page":"149","article-title":"Giant cell tumor of the tendon sheath: study of 64 cases and review of the literature","volume":"34","author":"Di Grazia","year":"2013","journal-title":"G Chir"},{"key":"10.1016\/j.clinthera.2018.03.001_bib3","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1007\/s11999-009-0922-7","article-title":"Pigmented villonodular synovitis of the knee","volume":"467","author":"Murphey","year":"2009","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clinthera.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00005792-198005000-00004","article-title":"Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review","volume":"59","author":"Myers","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors: a nationwide study in The Netherlands","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"10.1016\/j.clinthera.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon.13.124","article-title":"Pigmented villonodular synovitis; current concepts about diagnosis and management","volume":"9","author":"Verspoor","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib8","first-page":"335","article-title":"The pathogensis and long-term end results of pigmented villonodular synovitis","volume":"114","author":"Granowitz","year":"1976","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.clinthera.2018.03.001_bib9","first-page":"413","article-title":"Giant cell tumore of tendon sheath, tenosynovial giant cell tumore, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence","volume":"7","author":"Martin","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clinthera.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0360-3016(95)00514-Y","article-title":"Outcome following radiation treatment for high-risk pigmented villonodular synovitis","volume":"32","author":"O\u2019Sullivan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clinthera.2018.03.001_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdn033","article-title":"Complete response to imatinib in relapsing pigmented villonodular synovitisi\/tenosynovial giant cell tumor","volume":"19","author":"Blay","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1370\/afm.1364","article-title":"Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures","volume":"10","author":"Bayliss","year":"2012","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.clinthera.2018.03.001_bib15","article-title":"Consumer Price Index","year":"2012","journal-title":"Medical Care. Series ID: SUUR0000SAM"},{"key":"10.1016\/j.clinthera.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1002\/cncr.26529","article-title":"Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor\/pigmented villonodular synovitis with radiotherapy and surgery","volume":"118","author":"Griffin","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2018.03.001_bib17","first-page":"423","article-title":"Giant cell tumor of the tendon sheath: experience with 65 cases","volume":"12","author":"Adams","year":"2012","journal-title":"Eplasty"},{"key":"10.1016\/j.clinthera.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","article-title":"Patient-reported symptoms of tenosynovial giant cell tumors","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.clinthera.2018.03.001_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12593-010-0020-9","article-title":"Giant cell tumor of the tendon sheath: case series and review of the literature","volume":"2","author":"Suresh","year":"2010","journal-title":"J Hand Microsurg"},{"key":"10.1016\/j.clinthera.2018.03.001_bib20","first-page":"FC12","article-title":"Giant cell tumour of the tendon sheath: analysis of 35 cases and their Ki-67 proliferation indexes","volume":"8","author":"Bedir","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.clinthera.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11552-013-9518-5","article-title":"Benign upper extremity tumors: factors associated with operative treatment","volume":"8","author":"Sluijmer","year":"2013","journal-title":"Hand"},{"key":"10.1016\/j.clinthera.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/230949901101900218","article-title":"Giant cell tumor of the tendon sheath of the hand","volume":"19","author":"Garg","year":"2011","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"10.1016\/j.clinthera.2018.03.001_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","article-title":"Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R Axis","volume":"17","author":"Brahmi","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clinthera.2018.03.001_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/acr.22146","article-title":"Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study","volume":"66","author":"Lai","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T01:42:36Z","timestamp":1547689356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818300936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0149291818300936"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.03.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Illness Associated with Tenosynovial Giant Cell Tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}